Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Slightly Bearish -15

Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products

AI-generated analysis

🦠 Becton, Dickinson and Company (BDX) issued a voluntary recall on June 6, 2026, for specific lots of ChloraPrep and FREPP skin preparation applicators due to potential fungal contamination.

πŸ“… The recalled products, identified by lot numbers 4032183 and 4073005, were distributed to hospitals and suppliers between March and June 2024.

⚠️ The contamination involves Aspergillus penicillioides, which poses severe risks including systemic infection, sepsis, and surgical complications, though no adverse events have been reported yet.

πŸ“‰ Bank of America lowered its price target on BDX from $177 to $170 on June 12, 2026, citing lower utilization environments and inflation headwinds for 2027.

πŸ“Š The analyst firm reduced 2027 estimates across its large-cap medtech coverage to account for potential margin compression risks in the sector.

πŸ’¬ Jim Cramer expressed confidence in BDX earlier in June, stating the stock is selling at the lowest level he has ever seen and advising investors to buy while waiting for further price drops.

Bullish Signals
  • Jim Cramer views BDX as undervalued, noting it is selling at the lowest level he has ever seen.
  • The company intends to provide replacements for the recalled products, mitigating long-term supply chain disruption risks.
Risk Factors
  • Bank of America lowered its price target from $177 to $170 due to concerns over lower utilization environments and inflation headwinds.
  • The analyst firm reduced 2027 estimates across large-cap medtech coverage, signaling sector-wide margin compression risks.
  • A voluntary recall for specific lots of skin preparation products poses a direct operational and reputational risk due to potential fungal contamination.
Full Analysis
On June 6, 2026, Becton, Dickinson and Company (NYSE: BDX) issued a nationwide voluntary recall for specific lots of its ChloraPrep and FREPP skin preparation applicators due to potential fungal contamination by Aspergillus penicillioides. The affected lots, identified as 4032183 and 4073005, were distributed between March and June 2024 to hospitals and suppliers. While no adverse events have been reported yet, the company advises immediate cessation of use and destruction of the products, with replacements intended to be provided. In financial news, Bank of America lowered its price target on BDX from $177 to $170 on June 12, 2026, while maintaining a Neutral rating. The analyst cited a lower utilization environment and increased inflation headwinds for 2027 as reasons for adopting a more conservative outlook on medtech companies, specifically reducing 2027 estimates across large-cap coverage to account for potential margin compression risks. Jim Cramer expressed confidence in the stock earlier in June, noting that BDX is selling at the lowest level he has ever seen and suggesting investors buy while waiting to see if it oversells further. Despite these mixed signals regarding valuation and sentiment, the article concludes with promotional content for an investment newsletter rather than substantive analysis of the company's broader financial health or strategic position.